Cite
HARVARD Citation
Yang, X. et al. (2019). Inotuzumab ozogamicin as chemotherapy-sparing salvage in a 67-year-old man with primary refractory B-cell acute lymphoblastic leukemia with high-risk genomic features. Leukemia research reports. p. . [Online].